What is Calluna Pharma?
Calluna Pharma operates at the intersection of advanced immunology and drug discovery. By focusing on the underlying mechanisms of immunological disorders, the company aims to develop novel therapeutic interventions that address significant unmet medical needs. Its market position is bolstered by a rigorous scientific methodology and a commitment to translating complex biological insights into scalable pharmaceutical solutions. As a key entity within the Norwegian life sciences ecosystem, Calluna Pharma leverages its strategic location and research capabilities to compete on a global scale, targeting high-growth segments within the broader biopharmaceutical industry.
How much funding has Calluna Pharma raised?
Calluna Pharma has raised a total of $81.4M across 1 funding round:
Series A
$81.4M
Series A (2024): $81.4M with participation from Sarsia, Investinor, and Forbion
Key Investors in Calluna Pharma
Sarsia
Sarsia is an early-stage venture capital firm focused on investing in technologies and solutions that promote a greener and healthier future, with a specific emphasis on Life Sciences.
Investinor
Investinor AS collaborates with entrepreneurs and startups to develop promising businesses into world leaders, managing a significant portfolio with a focus on sustainable innovation.
Forbion
Forbion is a global life sciences venture capital firm that sources, builds, and guides biotech and biopharmaceutical companies from early stage through clinical development.
What's next for Calluna Pharma?
With this major enterprise-level funding, Calluna Pharma is well-positioned to scale its operational capacity and advance its lead candidates through critical clinical milestones. The strategic allocation of this capital will likely prioritize the expansion of its R&D infrastructure and the strengthening of its intellectual property portfolio. By aligning with top-tier life science investors, the company is set to enhance its clinical trial execution and potentially explore collaborative partnerships that could accelerate the commercialization of its therapeutic pipeline. The focus remains on achieving long-term value creation through scientific excellence and disciplined capital deployment in the competitive immunology sector.
See full Calluna Pharma company page
